Strategic funding Beyond Air has secured substantial funding and is actively extending its cash runway to accelerate deployment of its LungFit PH nitric oxide system, signaling ongoing investment readiness and potential for larger purchasing commitments.

Commercial readiness As a commercial stage medical device and biopharmaceutical company with a focus on nitric oxide delivery, Beyond Air is positioned to scale sales efforts and expand adoption in hospitals and clinics with respiratory and NICU applications.

Leadership cadence Recent executive appointments and investor engagement activity, including a new CFO and participation in major conferences, indicate a proactive stance to strengthen financial governance and attract strategic partnerships.

Expansion partnerships Strategic collaborations with institutions such as The Hebrew University of Jerusalem for preclinical programs and deployment in hospital NICUs point to opportunities for co-developed selling propositions and bundled offerings with academic and clinical partners.

Public market signals Regular investor events and visibility at industry conferences, coupled with a Nasdaq listing, suggest readiness for targeted outreach to institutional buyers and hospital systems seeking innovative NO-based therapies and respiratory solutions.